Base de dados : MEDLINE
Pesquisa : E02.547.800.500 [Categoria DeCS]
Referências encontradas : 569 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 57 ir para página                         

  1 / 569 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328637
[Au] Autor:Filipovic M; Gledovic A; Lukic M; Tasic-Kostov M; Isailovic T; Pantelic I; Vuleta G; Savic S
[Ti] Título:Alp Rose stem cells, olive oil squalene and a natural alkyl polyglucoside emulsifier: Are they appropriate ingredients of skin moisturizers - in vivo efficacy on normal and sodium lauryl sulfate - irritated skin?.
[So] Source:Vojnosanit Pregl;73(11):991-1002, 2016 11.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Since skin moisturization may be achieved by both actives and chosen carrier, plant stem cells, squalene and natural alkyl polyglucoside emulsifier may be potential components of contemporary cosmetic products. The aim of the study was in vivo evaluation of the skin irritation potential and the efficacy of Alpine Rose stem cells incorporated into li-posomes and olive oil squalene as ingredients of moisturizing creams, with respect to the novel emulsifier used for creams' stabilization. Methods: With the employment of noninvasive skin biophysical measurements, skin hydration (EC), transepi-dermal water loss (TEWL), erythema index (EI) and viscoelas-ticity were measured on 76 healthy volunteers. In the first phase, skin irritation after a 24-hour occlusion and the long-term efficacy of creams (a 21-day study) on healthy skin were evaluated. Phase II of the study focused on the cream efficacy assessment after a 6-day treatment of sodium lauryl sulfate-irritated skin. Results: After a 24-hour occlusion, there were no significant changes in the EI for any tested sample. In the second phase of the study, the EI was not significantly altered for the cream containing squalene, while the application of all active samples resulted in a significant reduction of TEWL. In both phases of the study an EC increase was recorded, espe-cially for the squalene-containing cream. Conclusion: Due to the lack of skin irritation and skin barrier impairment along with the marked hydration effect, it could be said that the in-vestigated actives incorporated into alkyl polyglucoside emulsi-fier-stabilized creams may be safely applied as ingredients for "tailor-made" cosmetic moisturizers intended for normal and dry skin care, whereas olive oil squalene could be used for the treatment of irritated or sensitive skin as well. [Projekat Ministarstva nauke Republike Srbije, br. TR34031]
[Mh] Termos MeSH primário: Emulsificantes/administração & dosagem
Glucosídeos/administração & dosagem
Azeite de Oliva/química
Rhododendron/citologia
Creme para a Pele/administração & dosagem
Testes de Irritação da Pele/métodos
Pele/efeitos dos fármacos
Dodecilsulfato de Sódio/toxicidade
Esqualeno/administração & dosagem
Células-Tronco/fisiologia
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Segurança de Produtos ao Consumidor
Método Duplo-Cego
Elasticidade
Emulsificantes/efeitos adversos
Feminino
Glucosídeos/efeitos adversos
Seres Humanos
Lipossomos
Fitoterapia
Plantas Medicinais
Medição de Risco
Sérvia
Pele/metabolismo
Pele/patologia
Creme para a Pele/efeitos adversos
Esqualeno/efeitos adversos
Esqualeno/isolamento & purificação
Fatores de Tempo
Viscosidade
Perda Insensível de Água/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Emulsifying Agents); 0 (Glucosides); 0 (Liposomes); 0 (Olive Oil); 368GB5141J (Sodium Dodecyl Sulfate); 7QWM220FJH (Squalene)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150116122F


  2 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29250537
[Au] Autor:Li Y; Xu W; Li L
[Ad] Endereço:Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
[Ti] Título:Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels.
[So] Source:Biomed Res Int;2017:3265024, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of the study was to investigate the efficacy and safety of halometasone cream to treat chronic generalized eczema and the effects of halometasone cream on serum cortisol (COR) levels. Sixty consecutive outpatients diagnosed with chronic generalized eczema between January and April 2017 were included and divided into groups A, B, and C with a lesion area of 30%-40%, 41%-50%, and 51%-60%, respectively. Groups A, B, and C were treated with halometasone cream with a daily dose of 15 g, 20 g, and 30 g for 7-14 days, respectively. Ten patients were randomly selected from each group for serum COR measurement at days 0, 7, and 14. On day 14, group B had significantly higher cure rate (47.1%) than groups A (17.9%) and C (13.3%) and significantly higher effectiveness rate (82.4%) than group C (40.0%) (all < 0.05). Serum COR levels were not affected in group A but were reduced significantly in groups B and C on days 7 and 14 (all < 0.05). No adverse reaction was observed. Halometasone cream appeared to relieve chronic generalized eczema effectively and safely. High dosage (≥20 g daily for 14 days) may temporarily reduce endogenous COR production substantially, although it may be more effective.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Betametasona/análogos & derivados
Eczema/tratamento farmacológico
Hidrocortisona/análise
[Mh] Termos MeSH secundário: Adulto
Idoso
Anti-Inflamatórios/efeitos adversos
Betametasona/efeitos adversos
Betametasona/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Creme para a Pele/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 9842X06Q6M (Betamethasone); J69Z9UU41Z (halometasone); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1155/2017/3265024


  3 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28877115
[Au] Autor:Wickett RR; Damjanovic B
[Ad] Endereço:R. Randall Wickett, PhD, James L. Winkle College of Pharmacy, Cincinnati, Ohio. Bronson Damjanovic, BS, Coloplast Corporation, Mankato, Minnesota.
[Ti] Título:Quantitation of 24-Hour Moisturization by Electrical Measurements of Skin Hydration.
[So] Source:J Wound Ostomy Continence Nurs;44(5):487-491, 2017 Sep/Oct.
[Is] ISSN:1528-3976
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of this study was to quantify the effects of several moisturizers on hydration of the stratum corneum by measuring their effect on electrical conductance over a 24-hour period. DESIGN: Double-blind, randomized controlled trial. SUBJECTS AND SETTING: Twenty-five healthy female volunteers aged 18 to 65 years with dry skin on the lower legs and no other known dermatologic pathology participated in the study. Additional exclusion criteria were pregnant or taking anti-inflammatory steroids. The study was carried out in a clinical research facility in Winnipeg, Manitoba, Canada. METHODS: Subjects underwent a 3-day conditioning period using a natural soap bar on the lower legs and no application of moisturizer to the skin. Participants then came to the test site and equilibrated for at least 30 minutes under controlled conditions of temperature and humidity. After baseline hydration measurements on test sites on the lower legs of each subject, a single application of each of 5 test products at a dose of 2 mg/cm was made. Skin hydration was assessed by electrical conductance measurements with a specialized probe. The probe was briefly placed on the skin surface with light pressure, and the measurement recorded in units of microsiemens (µS). Conductance was measured at 2, 4, 6, 8, and 24 hours after product applications. RESULTS: Although all but 1 of the test products increased conductance at 2 hours, only 2 moisturizers containing high levels of glycerin (products C and E) maintained increased conductance relative to baseline at 24 hours, +37.8 (P < .001) and +103.5 (P < .001), respectively. CONCLUSIONS: Moisturizers containing high levels of glycerin can provide a measurable moisturization benefit as determined by skin conductance for at least 24 hours after a single application.
[Mh] Termos MeSH primário: Condutividade Elétrica/classificação
Hipodermóclise/classificação
Creme para a Pele/normas
[Mh] Termos MeSH secundário: Adulto
Canadá
Método Duplo-Cego
Feminino
Glicerol/farmacologia
Glicerol/uso terapêutico
Seres Humanos
Creme para a Pele/farmacologia
Creme para a Pele/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
PDC6A3C0OX (Glycerol)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE
[do] DOI:10.1097/WON.0000000000000363


  4 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28837365
[Au] Autor:Patel NU; Shukla S; Zaki J; Feldman SR
[Ad] Endereço:a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
[Ti] Título:Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
[So] Source:Expert Rev Clin Pharmacol;10(10):1049-1054, 2017 Oct.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face. The symptom of persistent erythema can be particularly frustrating for both patients and physicians as it is difficult to treat. Areas covered: Current treatment options for the treatment of rosacea include metronidazole, azelaic acid, sodium sulfacetamide-sulfur, and brimonidine. Until recently, brimonidine gel was the only option approved specifically for the treatment of facial erythema. However, oxymetazoline hydrochloride 1% cream is a newly FDA approved topical medication for adult rosacea patients. A primarily alpha-1a agonist, oxymetazoline hydrochloride (HCl) is thought to diminish erythema through vasoconstriction. Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea. Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice. As further evidence becomes available, the real-world clinical potential of topical oxymetazoline cream will become clearer.
[Mh] Termos MeSH primário: Eritema/tratamento farmacológico
Oximetazolina/administração & dosagem
Rosácea/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Agonistas alfa-Adrenérgicos/administração & dosagem
Agonistas alfa-Adrenérgicos/efeitos adversos
Agonistas alfa-Adrenérgicos/farmacologia
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/efeitos adversos
Fármacos Dermatológicos/farmacologia
Eritema/etiologia
Eritema/patologia
Seres Humanos
Oximetazolina/efeitos adversos
Oximetazolina/farmacologia
Rosácea/patologia
Creme para a Pele
Vasoconstrição/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-Agonists); 0 (Dermatologic Agents); 8VLN5B44ZY (Oxymetazoline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1370370


  5 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28807114
[Au] Autor:Belum VR; Marchetti MA; Dusza SW; Cercek A; Kemeny NE; Lacouture ME
[Ad] Endereço:Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
[Ti] Título:A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.
[So] Source:J Am Acad Dermatol;77(3):577-579, 2017 09.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Erupções Acneiformes/prevenção & controle
Anti-Infecciosos/uso terapêutico
Antineoplásicos/efeitos adversos
Carcinoma de Células Escamosas/tratamento farmacológico
Cetuximab/efeitos adversos
Neoplasias Colorretais/tratamento farmacológico
Dapsona/uso terapêutico
Erupção por Droga/prevenção & controle
[Mh] Termos MeSH secundário: Erupções Acneiformes/induzido quimicamente
Adulto
Idoso
Carcinoma de Células Escamosas/secundário
Neoplasias Colorretais/patologia
Método Duplo-Cego
Erupção por Droga/etiologia
Dermatoses Faciais/induzido quimicamente
Dermatoses Faciais/prevenção & controle
Géis
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Qualidade de Vida
Creme para a Pele/uso terapêutico
Tórax
[Pt] Tipo de publicação:COMPARATIVE STUDY; LETTER; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Antineoplastic Agents); 0 (Gels); 8W5C518302 (Dapsone); PQX0D8J21J (Cetuximab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170816
[St] Status:MEDLINE


  6 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28771503
[Au] Autor:Foerster J; Boswell K; West J; Cameron H; Fleming C; Ibbotson S; Dawe R
[Ad] Endereço:University of Dundee, Medical School, Dundee, Scotland.
[Ti] Título:Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice.
[So] Source:PLoS One;12(8):e0181813, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary. AIMS: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. METHODS: The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis. RESULTS: Around 75% of patients both achieved a status of "clear/minimal disease" and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25%) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations. CONCLUSIONS: NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.
[Mh] Termos MeSH primário: Psoríase/terapia
Creme para a Pele/uso terapêutico
Esteroides/uso terapêutico
Terapia Ultravioleta
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
Prescrições de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Psoríase/tratamento farmacológico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Steroids)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181813


  7 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723852
[Au] Autor:Kon Y; Ichikawa-Shigeta Y; Iuchi T; Nakajima Y; Nakagami G; Tabata K; Sanada H; Sugama J
[Ad] Endereço:Yuka Kon, MHS, RN, Department of Clinical Nursing, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan. Yoshie Ichikawa-Shigeta, PhD, RN, Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Terumi Iuchi, PhD, RN, Department of Clinical Nursing, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan. Yukari Nakajima, MHS, RN, Department of Clinical Nursing, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan. Gojiro Nakagami, PhD, RN, Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Keiko Tabata, RN, Sengi Hospital, Asanogawa Medical Corporation, Kanazawa, Japan. Hiromi Sanada, PhD, WOCN, RN, Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Junko Sugama, PhD, RN, Advanced Health Care Science Research UnitInnovative Integrated Bio-Research CoreInstitute for Frontier Science Initiative, Kanazawa University, Ishikawa, Japan.
[Ti] Título:Effects of a Skin Barrier Cream on Management of Incontinence-Associated Dermatitis in Older Women: A Cluster Randomized Controlled Trial.
[So] Source:J Wound Ostomy Continence Nurs;44(5):481-486, 2017 Sep/Oct.
[Is] ISSN:1528-3976
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of this study was to examine the effects of a skin barrier cream with moisturization and skin-protectant characteristics for improving the severity of incontinence-associated dermatitis (IAD) pertaining to the skin physiology and appearance. We measured the following outcomes: (1) skin physiological characteristics indicating skin protection and enhancement of the skin's moisture barrier (stratum corneum hydration, dermis hydration level, transepidermal water loss, and skin pH); and (2) changes in skin appearance (the degree of erythema and pigmentation, and the sulcus cutis condition). DESIGN: Single-blind, cluster randomized controlled trial. SUBJECTS AND SETTING: The study was conducted in a long-term care facility in Japan between November 7, 2011, and May 6, 2012. We used block randomization to obtain a random sample of 6 (4 experimental and 2 control) out of 10 available wards. All subjects were elderly women with IAD of the buttock or inner thigh. We assessed 295 patients, but only 33 met inclusion criteria; 18 were allocated to the experimental group and 15 were allocated to the control group. METHODS: All participants were managed with cleansing with a skin cleanser and application of a moisturizer daily. In addition, a skin barrier cream designed to enhance the skin's moisture barrier and act as a protective barrier was applied to the skin of patients in the experimental group 3 times a day when absorptive briefs were changed. Skin physiological and appearance characteristics were scored only at the buttock or thigh area. All data were collected on days 1 and 14 of the study. RESULTS: Univariate analysis found that the erythema index was lower in the intervention group than in the control group at day 14 (P = .004). Multivariate analysis found significant associations between use of the skin barrier cream and increased stratum corneum hydration (ß= .443, P = .031), decreased skin pH (ß=-.439, P = .020), and magnitude of erythema (ß=-.451, P = .018). CONCLUSIONS: Study findings suggest that a barrier cream designed to enhance the skin's moisture barrier and act as a skin protectant increased stratum corneum hydration, reduced cutaneous pH, and reduced erythema.
[Mh] Termos MeSH primário: Dermatite/prevenção & controle
Dermatite/terapia
Creme para a Pele/normas
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Análise por Conglomerados
Incontinência Fecal/complicações
Feminino
Seres Humanos
Japão
Análise Multivariada
Casas de Saúde/estatística & dados numéricos
Método Simples-Cego
Creme para a Pele/uso terapêutico
Incontinência Urinária/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1097/WON.0000000000000353


  8 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28619556
[Au] Autor:Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
[Ad] Endereço:Department of Pediatrics, Division of Dermatology, Seattle Children's Hospital, Seattle, Washington. Electronic address: cbilinski@gmail.com.
[Ti] Título:Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
[So] Source:J Am Acad Dermatol;77(1):167-170, 2017 07.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopecia em Áreas/tratamento farmacológico
Janus Quinases/antagonistas & inibidores
Piperidinas/uso terapêutico
Inibidores de Proteínas Quinases/uso terapêutico
Pirazóis/uso terapêutico
Pirimidinas/uso terapêutico
Pirróis/uso terapêutico
[Mh] Termos MeSH secundário: Administração Cutânea
Adolescente
Pré-Escolar
Feminino
Seres Humanos
Masculino
Piperidinas/administração & dosagem
Inibidores de Proteínas Quinases/administração & dosagem
Pirazóis/administração & dosagem
Pirimidinas/administração & dosagem
Pirróis/administração & dosagem
Creme para a Pele/uso terapêutico
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (INCB018424); 0 (Piperidines); 0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 0 (Pyrimidines); 0 (Pyrroles); 87LA6FU830 (tofacitinib); EC 2.7.10.2 (Janus Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  9 / 569 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28601555
[Au] Autor:Thors L; Koch M; Wigenstam E; Koch B; Hägglund L; Bucht A
[Ad] Endereço:Swedish Defence Research Agency, Division of CBRN Defence and Security, Umeå, Sweden. Electronic address: lina.thors@foi.se.
[Ti] Título:Comparison of skin decontamination efficacy of commercial decontamination products following exposure to VX on human skin.
[So] Source:Chem Biol Interact;273:82-89, 2017 Aug 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:The decontamination efficacy of four commercially available skin decontamination products following exposure to the nerve agent VX was evaluated in vitro utilizing a diffusion cell and dermatomed human skin. The products included were Reactive Skin Decontamination Lotion (RSDL), the Swedish decontamination powder 104 (PS104), the absorbent Fuller's Earth and the aqueous solution alldecontMED. In addition, various decontamination procedures were assessed to further investigate important mechanisms involved in the specific products, e.g. decontamination removal from skin, physical removal by sponge swabbing and activation of degradation mechanisms. The efficacy of each decontamination product was evaluated 5 or 30 min after dermal application of VX (neat or diluted to 20% in water). The RSDL-lotion was superior in reducing the penetration of VX through human skin, both when exposed as neat agent and when diluted to 20% in water. Swabbing with the RSDL-sponge during 2 min revealed decreased efficacy compared to applying the RSDL-lotion directly on the skin for 30 min. Decontamination with Fuller's Earth and alldecontMED significantly reduced the penetration of neat concentration of VX through human skin. PS104-powder was insufficient for decontamination of VX at both time-points, independently of the skin contact time of PS104. The PS104-slurry (a mixture of PS104-powder and water), slightly improved the decontamination efficacy. Comparing the time-points for initiated decontamination revealed less penetrated VX for RSDL and Fuller's Earth when decontamination was initiated after 5 min compared to 30 min post-exposure, while alldecontMED displayed similar efficacy at both time-points. Decontamination by washing with water only resulted in a significant reduction of penetrated VX when washing was performed 5 min after exposure, but not when decontamination was delayed to 30 min post-exposure of neat VX. In conclusion, early initiated decontamination with the RSDL-lotion, containing both absorption and degrading properties, allowed to act on skin for 30 min was superior in preventing VX from penetrating human skin. Adding water during decontamination resulted in increased penetration of neat VX, however, water in the decontaminant removal process did not influence the decontamination efficacy. From our study on commercially available decontaminants, it is recommended that future product developments should include both strong absorbents and efficient nerve agent degrading components.
[Mh] Termos MeSH primário: Substâncias para a Guerra Química/análise
Descontaminação/métodos
Compostos Organotiofosforados/administração & dosagem
Compostos Organotiofosforados/análise
Creme para a Pele/administração & dosagem
Pele/metabolismo
[Mh] Termos MeSH secundário: Substâncias para a Guerra Química/efeitos adversos
Seres Humanos
Técnicas In Vitro
Pele/efeitos dos fármacos
Absorção Cutânea/efeitos dos fármacos
Creme para a Pele/farmacologia
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chemical Warfare Agents); 0 (Organothiophosphorus Compounds); 9A4381183B (VX)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE


  10 / 569 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535935
[Au] Autor:Dolezal P; Kyjaková P; Valterová I; Urban S
[Ad] Endereço:Department of Analytical Chemistry, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: dolezald@vscht.cz.
[Ti] Título:Qualitative analyses of less-volatile organic molecules from female skin scents by comprehensive two dimensional gas chromatography-time of flight mass spectrometry.
[So] Source:J Chromatogr A;1505:77-86, 2017 Jul 07.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Instrumental human scent analysis is undoubtedly desirable for many forensic as well medical applications. Most of the previous human scent studies were focused on volatile organic compounds (VOCs) which were analysed by head space solid phase micro-extraction gas chromatography/mass spectrometry (HS-SPME-GC/MS). This method is, however, significantly less sensitive to "heavier" less volatile compounds emitted from the human skin. These less volatile organic scent molecules probably create the basis of the individual human scent signature, and therefore, our attention is focused mainly on these "heavier" compounds. The human scent was adsorbed onto purified glass beads and samples were prepared as hexane solutions obtained by extraction from the sampled glass beads. To resolve a lot of very similar molecules, the comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometer (GCxGC-TOFMS) was used to analyse the hexane scent solutions. Using this technique, more than 137 less volatile molecules including organic fatty acids, ketones, aldehydes, simple esters, alcohols, and especially various fatty acid esters with different carbon chains were identified. A considerable number of these molecules were identified in the scent samples for the first time.
[Mh] Termos MeSH primário: Cromatografia Gasosa-Espectrometria de Massas/métodos
Creme para a Pele/química
Compostos Orgânicos Voláteis/química
[Mh] Termos MeSH secundário: Adsorção
Feminino
Cromatografia Gasosa-Espectrometria de Massas/instrumentação
Seres Humanos
Microextração em Fase Sólida/métodos
Compostos Orgânicos Voláteis/isolamento & purificação
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Volatile Organic Compounds)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE



página 1 de 57 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde